Scarica l'app Stockscreener
2.385
2.86%
-0.065
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.45
Aprire:
$2.45
Volume 24 ore:
3.46M
Relative Volume:
0.23
Capitalizzazione di mercato:
$863.02M
Reddito:
$32.77M
Utile/perdita netta:
$-440.22M
Rapporto P/E:
-1.4281
EPS:
-1.67
Flusso di cassa netto:
$-400.48M
1 W Prestazione:
-5.93%
1M Prestazione:
-23.96%
6M Prestazione:
-54.75%
1 anno Prestazione:
-79.12%
Intervallo 1D:
$2.36
$2.50
Intervallo di 1 settimana:
$2.36
$2.76
Portata 52W:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Confronta IOVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.385 | 915.49M | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.81 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.70 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.04 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
705.59 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.48 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Multi factor analysis applied to Iovance Biotherapeutics Inc.July 2025 Reactions & Free Safe Capital Growth Stock Tips - Newser
How to build a custom watchlist for Iovance Biotherapeutics Inc.Weekly Risk Report & Free Risk Controlled Daily Trade Plans - Newser
Is this a good reentry point in Iovance Biotherapeutics Inc.Weekly Investment Report & Fast Entry Momentum Alerts - Newser
Will Iovance Biotherapeutics Inc. continue its uptrend2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
Combining machine learning predictions for Iovance Biotherapeutics Inc.July 2025 PreEarnings & Long Hold Capital Preservation Plans - Newser
Can momentum traders help lift Iovance Biotherapeutics Inc.Quarterly Profit Report & Free Safe Capital Growth Stock Tips - Newser
What to do if you’re stuck in Iovance Biotherapeutics Inc.Rate Cut & Low Risk Growth Stock Ideas - Newser
Will Iovance Biotherapeutics Inc. bounce back from current supportQuarterly Risk Review & Daily Chart Pattern Signal Reports - Newser
Iovance Biotherapeutics Inc. stock daily chart insightsDollar Strength & Community Driven Trade Alerts - Newser
Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
Can Iovance Biotherapeutics Inc. rally from current levelsJuly 2025 Institutional & Expert Approved Trade Ideas - Newser
Iovance Biotherapeutics Secondary Stock Offering: A $350M Deal with a 6% Share Price Drop - AInvest
IOVA Stock Drops 6% on $350M Common Stock Offering - TradingView
Risk vs reward if holding onto Iovance Biotherapeutics Inc.Portfolio Gains Summary & Safe Entry Zone Identification - Newser
Will Iovance Biotherapeutics Inc. benefit from macro trendsJuly 2025 Highlights & AI Driven Price Predictions - Newser
Chart based analysis of Iovance Biotherapeutics Inc. trendsExit Point & AI Powered Buy/Sell Recommendations - Newser
Is Iovance Biotherapeutics Inc. a candidate for recovery playJuly 2025 Decliners & Consistent Growth Equity Picks - Newser
Is Iovance Biotherapeutics Inc. forming a bottoming basePortfolio Gains Summary & Free Safe Entry Trade Signal Reports - Newser
Why Iovance Biotherapeutics Stock Got Mashed on Monday - AOL.com
Artisan Small Cap Fund Exited Its Stake in Iovance Biotherapeutics (IOVA) Due to Operational Challenges - Insider Monkey
How to forecast Iovance Biotherapeutics Inc. trends using time seriesIndex Update & Safe Entry Zone Tips - Newser
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street - AOL.com
Price momentum metrics for Iovance Biotherapeutics Inc. explainedJuly 2025 Drop Watch & AI Powered Market Entry Strategies - Newser
Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada - MSN
Iovance Biotherapeutics' $350M ATM Financing: A High-Stakes Bet on Amtagvi's Future - AInvest
Iovance Biotherapeutics Amends Sale Agreement with Jefferies - TipRanks
Iovance Biotherapeutics Grants Inducement Stock Options to New Employees - Quiver Quantitative
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics: Navigating the High-Risk, High-Reward Path of Amtagvi Global Expansion - AInvest
Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 (NASDAQ:IOVA) - Seeking Alpha
Detecting support and resistance levels for Iovance Biotherapeutics Inc.Weekly Market Report & Safe Entry Point Identification - Newser
Around the Helix: Cell and Gene Therapy Company Updates – August 20, 2025 - CGTLive®
Iovance Biotherapeutics Receives Health Canada Approval for Amtagvi in Advanced Melanoma Patients - AInvest
Statistical indicators supporting Iovance Biotherapeutics Inc.’s strengthPortfolio Risk Report & Real-Time Market Trend Scan - Newser
Iovance Biotherapeutics Gains Health Canada Approval - MSN
Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) Over Potential Securities Fraud Allegations - 28/22 News
Real time social sentiment graph for Iovance Biotherapeutics Inc.2025 Geopolitical Influence & Consistent Growth Equity Picks - Newser
Iovance Biotherapeutics’ TIL Therapy Lifileucel Approved for Advanced Melanoma in Canada - CGTLive®
Unexpected Surge: Analyzing Iovance’s Performance - StocksToTrade
Why Iovance Biotherapeutics Stock Was Climbing Today - Mitrade
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ - Stocktwits
Iovance Biotherapeutics’ Tumor Therapy Earns Key Approval - timothysykes.com
Iovance Stock Soars 21.2% on Amtagvi Approval - AInvest
Visual trend scoring systems applied to Iovance Biotherapeutics Inc.Weekly Trade Review & Detailed Earnings Play Alerts - Newser
Iovance gets conditional Health Canada approval for Amtagvi - MSN
Health Canada approves Iovance’s Amtagvi for advanced melanoma By Investing.com - Investing.com India
Iovance Says Amtagvi Gets Health Canada Clearance for Advanced Melanoma - MarketScreener
Health Canada approves Iovance’s Amtagvi for advanced melanoma - Investing.com
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma - The Manila Times
Iovance Biotherapeutics Receives Health Canada Approval for Amtagvi® T Cell Therapy for Advanced Melanoma - Quiver Quantitative
Iovance's Amtagvi receives Health Canada approval for advanced melanoma - MarketScreener
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Iovance Biotherapeutics Inc Azioni (IOVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
| Vogt Frederick G | Interim CEO & General Counsel |
May 14 '25 |
Buy |
1.69 |
25,000 |
42,250 |
374,646 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 14 '25 |
Option Exercise |
0.00 |
8,334 |
0 |
203,761 |
| Bellemin Jean-Marc | Chief Financial Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
58,590 |
0 |
87,938 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,106 |
0 |
120,880 |
0.39%
8.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):